An Amazing Way to Profit Big…
And Protect 50 Million American Men from
Deadly Prostate Cancer!
Major Announcement – Due by September 30 – Could Ignite a 72,500% Sales Surge for
Tiny $7 Company!
This life-saving technology could help protect me, you, and 50 million American men from deadly prostate cancer.
As I mentioned, Phase 3 trial results are due by September 30, and could launch this tiny $7 company toward a 72,500% sales surge.
Already, savvy biotech insiders – including the company’s President and Vice President – have snapped up nearly 90% of available shares.
In addition, some of the savviest players on Wall Street – JPMorgan, BlackRock, and Citibank – have taken massive stakes in this tiny $7 company.
And now, a $900 billion Swiss multinational investment bank just ramped up their stake in this tiny $7 company by a stunning 4,000%.
It’s no surprise…
Remember, prostate cancer is rampant in men over 50.
And because the existing PSA test can have a horrifying 80% FAIL RATE, scores of American men are walking around with cancer and don’t even know it!
As a result, prostate cancer kills every 18 minutes on average!
Thankfully, the revolutionary new Bounty Hunter test has a mind-blowing 94% accuracy rate!
It’s non-invasive, and detects prostate cancer in its earliest stages! Plus, it can spot cancer that has spread into other parts of the body. In other words, it covers all the bases!
And it gets better because this tiny $7 company is developing a cancer treatment that could not only fight prostate cancer, but could one day be used to defeat nearly every form of cancer!
The upside potential is unprecedented…
Right now, this tiny $7 company has a mere $12 million in annual revenue.
But when all is said and done, this tiny $7 small cap could disrupt the entire $100 billion cancer-treatment market.
Even if they capture a mere 1% of all markets, they’d see a staggering 72,500% sales surge.
Remember, startup companies that have developed life-saving tests have shown early investors massive gains, including…
10,400% on Accelerate Diagnostics…
15,000% on Bio-Rad…
And 23,000% on Illumina.
This tiny $7 company could put those gains to shame. And in the coming days, I expect to see shares go absolutely vertical.
n fact, critical Phase 3 trial results are due by September 30, and results could be leaked any day now.
When that happens, this tiny $7 stock could double to $14 overnight, surge to $28 by week’s end, and hit $56 in the blink of an eye.
Folks who get in now could make 5, 10, even 15 times their money.
Editor, Biotech Insider Alert
This is a discussion topic or guest posting submitted by a Stock Gumshoe reader. The content has not been edited or reviewed by Stock Gumshoe, and any opinions expressed are those of the author alone.